



DAY 1: Global Infectious Disease Landscape & Phage Therapy

Time	Speaker	Organization	Presentation
09:00-09:15	Dr. Frenk Smrekar	JAFRAL	<i>Welcome speech</i>
09:15-09:30	Mr Pietro Erba & Mr. Antony Rodiadis	European Commission	<i>New EU pharmaceutical legislation: prospects and opportunities for phage therapies</i>
09:30-10:00	Dr. Nina Graselli Kmet	University Medical Centre Ljubljana	<i>AMR today and tomorrow - epidemiology review and outlook for the future</i>
10:00-10:30	Dr. Balint Kintsens	HUN-REN Biological Research Centre	<i>From tracking nosocomial spread to scaling phage therapy: genomic surveillance of critically resistant pathogens</i>
10:30-11:00	Ms. Tine Rikke Jørgensen	Former WHO, University of Copenhagen	<i>Phage Vintage Innovation; A One Health Approach to Public Health Challenges</i>
11:00-11:30	Coffee break		
11:30-12:00	Dr. Rob Lavigne	Katholieke Universiteit Leuven	<i>Implementing personalized magistral phage treatments at KU/UZ Leuven</i>
12:00-12:30	Dr. Jochem Spoor	Erasmus Medical Center Rotterdam	<i>Study into neurotoxicity of bacteriophage</i>
12:30-13:00	Dr. Zuzanna Kaźmierczak	Hirszfeld Institute of Immunology and Experimental Therapy	<i>Phages and the Immune System</i>
13:00-14:00	Lunch		
14:00-14:30	Dr. Tobi Nagel	Phages for Global Health	<i>Utilizing Phages to Combat AMR in Africa and Asia</i>
14:30-15:00	Dr. Chantal Morel	University of Bern	<i>Lytic Potential, Systemic Inertia: Financing and Valuing Phages in Modern Health Systems</i>
15:00-15:30	Dr. Evelien Adriaenssens	Quadram Institute	<i>Do we agree or disagree on phage taxonomy? Considerations for clinical practice and regulation</i>
15:30-16:00	Coffee break		
16:00-16:45	Round Table	<i>AMR in practice: perspective from different countries</i>	



DAY 2: Clinical Trials & Current Results

Time	Speaker	Organization	Title
09:00-09:30	Dr. Christian Grøndahl	SNIPR Biome	<i>Developing CRISPR-armed phages (CAPs) for treating multi-drug resistant infections</i>
09:30-10:00	Dr. Radu Botgros	EMA	<i>Regulatory Expectations for Approval of Phage Therapy Medicinal Products in the European Union.</i>
10:00-10:30	Dr. Carmen Coxon	MHRA	<i>Regulation of phages – information, innovation, and insights</i>
10:30-11:00	Dr. Shawna McCallin	Balgrist University Hospital	<i>Academia's role in phage development</i>
11:00-11:30	Coffee Break		
11:30-12:00	Dr. Alexander Sulakvelidze	Intralytix	<i>Advancing Phage Therapeutics: Intralytix's Integrated Discovery-to-Clinic Platform.</i>
12:00-12:30	Dr. Minmin Yen	PhagePro	<i>Defining the Pathway for Phage Therapeutics in Global Health: Translating Outbreak Prevention from Concept to Clinic</i>
12:30-13:00	Dr. Stefan Vermeulen	HOGENT University of Applied Sciences and Arts	<i>Standardising and automating quantification and susceptibility testing of phages</i>
13:00-14:00	Lunch		
14:00-14:30	Dr. Frenk Smrekar	JAFRAL	<i>Production of phage products for Clinical trial and Personalized use</i>
14:30-15:00	Dr. Neha Prasad	Neha Consulting	<i>Regulatory perspectives and reimbursement models for alternative antimicrobials</i>
15:00-15:45	Round Table	<i>Key considerations in phage trial design</i>	
15:45-16:15	Coffee Break		
16:15-17:00	Poster Session		



DAY 3: Compassionate Use & Magistral Preparations

Time	Speaker	Organization	Title
09:00–09:30	Ms. Karen Northshield	Patient successfully treated with phage therapy	<i>"The Terrorist Attack, The Infection, and the Phage Miracle that saved my life" by Karen Northshield (Miracle Survivor of March 22nd, 2016)</i>
09:30–10:00	Dr. Anaïs Eskenazi	Medaïs	<i>Beyond the Protocol: One Patient, One Breakthrough, The Helsinki Compass</i>
10:00–10:30	Dr. Mzia Kutateladze	George Eliava Institute of Bacteriophages	<i>Personalized phage therapy at the Eliava Phage Therapy Center</i>
10:30–11:00	Dr. Jean-Paul Pirnay	Queen Astrid Military Hospital	<i>The Magistral Phage</i>
11:00–11:30	Coffee break		
11:30–12:00	Dr. Silvia Würstle	Frankfurt University Hospital	<i>New guidelines on personalized phage therapy</i>
12:00–12:30	Dr. Kārlis Rācenis	Rīga Stradiņš University	<i>Fighting Superbugs in War Wounds: Personalized Phage Therapy for MDR Klebsiella pneumoniae Osteomyelitis</i>
12:30–13:00	Dr. Andrej Trampuž	Queensland University of Technology (QUT)	<i>Opportunities, challenges, and limitations of bacteriophage treatment in bone and implant infections</i>
13:00–13:45	Lunch		
13:45–14:30	Round Table	<i>Practical approaches to patient treatment: how to initiate magistral phage treatment</i>	
14:30–15:00	Dr. Mark Sutton	UKHSA	<i>UKHSA Phage service; developing a framework to support clinical translation of phage.</i>
15:00–15:30	Dr. Steffen Langwald	BG Klinikum Bergmannstrost Halle	<i>The use of Bacteriophage Therapy in Septic Trauma Surgery</i>
15:30–16:00	Dr. Justus Groß	Universitätsmedizin Rostock	<i>Phage Therapy in Vascular Surgery</i>
16:00–17:00	Closing remarks & coffee		